en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">To explore the key targets and regulatory mechanisms affecting the efficacy of radiotherapy (RT) in patients with renal carcinoma (RCC) complicated by renal failure. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods:&nbsp;</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Differentially expressed genes (DEGs)(|log2FC|>2) in TCGA (n=537) and GEO data set (n=215) were screened by limma package in R software. Intersecting genes were accessed through the online site (InteractiVenn). The STRING and MCODE module of the Metascape website were used for key target screening and enriched pathway analysis. The preprocessCore R package was used for data normalization and batch effect processing. The survival/survminer R package was used to analyze the relationship between gene expression and patient survival. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results:&nbsp;</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">High expression of ACADM, DLAT, SUCLA2 and SUCLG2 genes were all associated with significantly improved prognosis in renal cancer patients. The mOS time in the ACADM high expression group was 7.10 years [Hazard Ratio (HR) = 0.466, 95% Confidence Interval (CI): 0.353-0.615). The mOS time in the DLAT high expression group was 7.10 years (HR=0.489, 95% CI: 0.372-0.642). The mOS time in the SUCLA2 high expression group was 7.30 years (HR=0.458, 95% CI: 0.346-0.606). The mOS time in the SUCLG2 group was 7.00 years (HR=0.544, 95% CI: 0.415-0.715). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion:&nbsp;</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The suppression of&nbsp;ACADM,&nbsp;DLAT,&nbsp;SUCLA2, and&nbsp;SUCLG2&nbsp;can regulate fatty acid metabolism and tricarboxylic acid cycle-related pathways, which provides ideas for the prognosis of patients with RCC complicated by renal failure.</span></span></span></span></span></span></span></span></span></div> Prognosis, radiotherapy, renal carcinoma, renal failure. 839 845 http://ijrr.com/browse.php?a_code=A-10-1-1405&slc_lang=en&sid=1 J. Wei 7900319475328460032151 7900319475328460032151 No Department of Nephrology, Zibo First Hospital, Zibo Shandong, China P. Gao 7900319475328460032152 7900319475328460032152 No Department of Nephrology, Zibo First Hospital, Zibo Shandong, China Z. Wang 7900319475328460032153 7900319475328460032153 No Department of Chinese Medicine, Zibo First Hospital, Zibo Shandong, China L. Fan 7900319475328460032154 7900319475328460032154 No Hemodialysis Center, Zibo First Hospital, Zibo Shandong, China J. Zhao zhaojin8490@dingtalk.com 7900319475328460032155 7900319475328460032155 Yes Department of Nephrology, Zibo First Hospital, Zibo Shandong, China